Company Profile

Company Description

LIXTE BIOTECHNOLOGY HOLDINGS, INC. is a clinical-stage biopharmaceutical firm focused on developing novel cancer therapies. The company specializes in small molecule inhibitors targeting key signaling pathways involved in tumor growth and resistance. Its lead compounds aim to enhance the effectiveness of existing treatments, particularly for aggressive and treatment-resistant cancers. By leveraging innovative research, the company seeks to improve patient outcomes in oncology. Its pipeline includes potential therapies for various solid tumors and hematologic malignancies. The firm collaborates with academic and industry partners to advance its drug candidates through clinical trials. Its work emphasizes precision medicine and personalized treatment approaches for cancer patients.